Abstract
One hundred ambulant outpatients with active, endoscopically proven peptic ulceration entered a double-blind trial of either tripotassium-dicitratobismuthate or placebo. Thirty-four patients had gastric ulceration, 56 had duodenal ulceration, three had both gastric and duodenal ulcers, and two had stomal ulceration. Five patients with gastric ulceration were withdrawn from the trial. Three patients with both gastric and duodenal ulceration and two patients with stomal ulceration were excluded from statistical analysis. After 28 days of tripotassium-dicitratobismuthate 94% of gastric ulcer patients had significant endoscopic healing (P<0.01). Although 75% of duodenal ulcers healed after 28 days of tripotassium-dicitratobismuthate, this was not statistically significant because of a 60% rate of healing with placebo. Tripotassium-dicitratobismuthate produced a significantly quicker symptomatic response in duodenal ulcer patients (P<0.01). No serious side effects were recorded, and patient acceptability was high. It is concluded that tripotassium-dicitratobismuthate is an effective agent for promoting gastric ulcer healing and for symptomatic relief in duodenal ulceration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Salmon PR, Brown P, Williams R, Read AE: Evaluation of colloidal bismuth (De Nol) in the treatment of duodenal ulcer employing endoscopic selection and follow up. Gut 15:189–193, 1974
Shreeve DR: A double-blind study of tri-potassium di-citrate bismuthate in duodenal ulcer. Postgrad Med J Suppl 5 51:33–36, 1975
Boyes BE, Woolf IL, Wilson RY, Cowley DJ, Dymock IW: Proceeding: Effective treatment of gastric ulceration with a Bismuth preparation (De Nol). Gut 15:833, 1974
Lee SP, Nicholson GI: Increased healing of gastric and duodenal ulcers in a controlled trial using tripotassiumdicitrato-bismuthate. Med J Aust 1:808–812, 1977
Gray GR, Smith IS, McKenzie I, Crean GP: Oral cimetidine in severe duodenal ulceration. A double-blind controlled trial. Lancet 1:4–7, 1977
Gibinski K, Rybicka J, Mikoś E, Mowat A: Double-blind clinical trial on gastroduodenal ulcer healing with prostaglandin E2 analogues. Gut 18:636–639, 1977
Peterson WL, Sturdevant RA, Frankl HD, Richardson CT, Isenberg JI, Elashoff JD, Sones JQ, Gross RA, McCallum RW, Fordtran JS: Healing of duodenal ulcer with an antacid regimen. N Engl J Med 297:341–345, 1977
Wormsley KG: Testing anti-ulcer drugs. Lancet 2:719, 1977
Burland WL, Simkins MA (eds): Cimetidine. New York, Oxford University Press, 1977
Williams DR: Analytical and computer simulation studies of colloidal bismuth citrate system used as an ulcer treatment. J Inorg Nucl Chem 39:711–714, 1977
Connell AM: Clinical Tests of Gastric Function. London, Pitman Medical, 1973
Wilson TR: The pharmacology of tri-potassium di-citrato bismuthate (TDB). Postgrad Med J Suppl 5 51:18–21, 1975
Burns R, Thomas DW, Barron VJ: Reversible encephalopathy possibly associated with bismuth subgallate ingestion. Br Med J 1:220–223, 1974
Mowat NAG, Needham CD, Brunt PW: The natural history of gastric ulcer in a community: A four-year study. Q J Med 44:45–56, 1975
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Glover, S.C., Cantlay, J.S., Weir, J. et al. Oral tripotassium-dicitratobismuthate in gastric and duodenal ulceration. Digest Dis Sci 28, 13–17 (1983). https://doi.org/10.1007/BF01393355
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01393355